PD20-05 CORRELATES OF KNOWLEDGE OF CLINICAL TRIALS AMONG UROLOGIC CANCER SURVIVORS: FINDINGS FROM THE HEALTH INFORMATION NATIONAL TRENDS SURVEY

Abstract

You have accessJournal of UrologyCME1 Apr 2023PD20-05 CORRELATES OF KNOWLEDGE OF CLINICAL TRIALS AMONG UROLOGIC CANCER SURVIVORS: FINDINGS FROM THE HEALTH INFORMATION NATIONAL TRENDS SURVEY Hanna Jia, Daniel Roberson, Leilei Xia, James Ding, Thomas Guzzo, and Daniel Lee Hanna JiaHanna Jia More articles by this author , Daniel RobersonDaniel Roberson More articles by this author , Leilei XiaLeilei Xia More articles by this author , James DingJames Ding More articles by this author , Thomas GuzzoThomas Guzzo More articles by this author , and Daniel LeeDaniel Lee More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003286.05AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Clinical trials remain the gold standard for evaluating therapeutic interventions. However, diversity and representation in clinical trials remains very low. Therefore, it is essential to understand potential factors that are associated with knowledge or awareness of clinical trials. METHODS: The National Cancer Institute’s Health Information National Trends Survey (HINTS) 5 was evaluated. Data from Cycles 1 (2017) and 4 (2020) were obtained. General interaction with healthcare providers and the internet was evaluated, and knowledge of clinical trials were evaluated. Multivariable logistic regression models were used to examine clinical trial knowledge after adjusting for sociodemographic characteristics such as age, gender, income, and census region. RESULTS: Of the 200 prostate, kidney, and bladder cancer survivors, 32 (16%) were Non-hispanic Black, 24 (12%) were Hispanic, and 14 (7%) were Asian / Other. Thirty-two percent of the cancer survivors stated having no knowledge of clinical trials. When asked about potential factors that would influence the decision to join a clinical trial, urologic cancer survivors reported a much lower potential influence of getting paid (41% vs 27%) and support in the form of transportation or childcare (45% vs. 31%), but a much higher influence of a doctor recommendation (38% vs. 30%) compared to non-cancer survivors (all p<0.01). Only 4.5% of urologic cancer survivors reported knowledge of the ClinicalTrials.gov website. In adjusted logistic regression analysis, Hispanics (OR 0.26, p<0.01) had significantly lower odds of clinical trial knowledge than Non-hispanic Whites. Having a provider who discussed clinical trials (OR 3.85, p=0.03) and having a lot of trust in the provider (OR 9.9, p=0.01) were significantly associated with knowledge of clinical trials. Respondents who reported needing a lot of effort to obtain medical information had a significantly lower odds of having knowledge of clinical trials (OR 0.04, p=0.01). CONCLUSIONS: Knowledge of clinical trials remains low among urologic cancer survivors. This is particularly true among Hispanic patients and those who reported difficulty obtaining medical information. Improving access to and awareness of knowledge sources, such as the ClinicalTrials.gov website, may improve knowledge of clinical trials. Importantly, providers could play a large role in decreasing this knowledge disparity. Use of this information may be helpful to decrease disparities in clinical trial enrollment. Source of Funding: None © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e585 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Hanna Jia More articles by this author Daniel Roberson More articles by this author Leilei Xia More articles by this author James Ding More articles by this author Thomas Guzzo More articles by this author Daniel Lee More articles by this author Expand All Advertisement PDF downloadLoading ...